Characteristics of studies included in this review
| Author (year) (reference) | Number of patients | Randomisation BMC versus placebo | Mean age (years) | Male (%) | LAD (%) | Primary intervention | Baseline LVEF (%) | Imaging Modality for LVEF Assessment | Follow-up (months)* |
| Cao et al (2009)4 | 86 | 1:1 | 51 | 94 | 100 | PCI | a) 41±3, b) 41±3 | TTE | 6, 48 |
| Castellani et al (2010)5 | 10 | 1:1 | 54 | 100 | 100 | PCI | a) 37±5, b) 38±7 | PET | 6, 12 |
| Ge et al (2006)6 | 20 | 1:1 | 59 | 90 | 70 | PCI | a) 54±9, b) 58±8 | TTE | 6 |
| Grajek et al (2010)7 | 45 | 2:1 | 50 | 87 | 100 | PCI | a) 45±10, b) 43±7 | EF-RNV | 3, 6, 12 |
| Hirsch et al (2010)8 | 134 | 1:1 | 56 | 84 | 61 | PCI | a) 44±9, b) 42±8 | MRI | 4 |
| Huikuri et al (2008)9 | 80 | 1:1 | 59 | 88 | 40 | Trombolysis followed by PCI | a) 59±11, b) 62±12 | LV Angio | 6 |
| Janssens et al (2006)10 | 67 | 1:1 | 57 | 82 | 63 | PCI | a) 49±7, b) 47±8 | MRI | 4, 12 |
| Karpov et al (2005)11 | 44 | 1:1 | 54 | 82 | 64 | PCI or trombolysis | Not reported | SPECT | 6 |
| Lunde et al (2006)12–14 | 100 | 1:1 | 57 | 84 | 100 | PCI | a) 55±14, b) 54±12 | MRI | 6, 12, 36 |
| Meluzin et al LD (2006)15 | 44 | 1:1 | 55 | 95 | 70 | PCI | a) 42±9, b) 42±9 | SPECT | 3, 6, 12 |
| Meluzin et al HD (2006)15 | 44 | 1:1 | 55 | 89 | 73 | PCI | a) 41±9, b) 42±9 | SPECT | 3, 6,12 |
| Noguiera et al (2009)16 | 20 | 2:1 | 59 | 70 | 60 | PCI or trombolysis | a) 48±10, b) 48±14 | TTE | 6 |
| Penicka et al (2007)17 18 | 27 | 2:1 | 59 | 81 | 100 | PCI | a) 39±6, b) 39±4 | TTE | 4, 24 |
| Piepoli et al (2010)19 | 38 | 1:1 | 65 | 68 | 100 | PCI | a) 37±9, b) 38±10 | SPECT | 6, 12 |
| Plewka et al (2009)20 21 | 60 | 2:1 | 56 | 70 | 100 | PCI | a) 35±6, b) 33±7 | TTE | 6, 12,24 |
| Quyyumi et al (2011)22 | 31 | 1:1 | 52 | 87 | Not reported | PCI | a) 48±10, b) 53±10 | MRI | 6 |
| Roncalli et al (2010)23 | 101 | 1:1 | 56 | 85 | 94 | PCI | a) 37±10, b) 39±9 | MRI | 3 |
| Schachinger et al (2006)24–26 | 204 | 1:1 | 56 | 82 | 70 | PCI | a) 48±9, b) 47±10 | LV angio, MRI | 4, 12, 24 |
| Tendera et al NS (2009)27 | 120 | 2:1 | 56 | 72 | 100 | PCI | a) 34 (19–44), b) 39 (23–44) | MRI | 6 |
| Tendera et al S (2009)27 | 120 | 2:1 | 58 | 68 | 100 | PCI | a) 35 (12–45), b) 39 (23–44) | MRI | 6 |
| Traverse et al (2010)28 | 40 | 3:1 | 54 | 78 | 100 | PCI | a) 49±10, b) 49±9 | MRI | 6 |
| Traverse et al (2011)29 | 87 | 2:1 | 57 | 83 | 91 | PCI | a) 49±12, b) 45±10 | MRI | 6 |
| Turan et al (2012)30 | 62 | 2:1 | 61 | 68 | 61 | PCI | a) 43±10, b) 45±10 | LV angio | 3, 12 |
| Wohrle et al (2010)31 32 | 42 | 2:1 | 61 | 81 | 50 | PCI | a) 54±9, b) 56±9 | MRI | 6, 12, 36 |
| Wollert et al (2004)33–35 | 60 | 1:1 | 56 | 70 | 64 | PCI | a) 50±10, b) 51±9 | MRI | 6, 18, 60 |
| Yao et al (2009)36 | 24 | 1:1 | 52 | 88 | 100 | PCI | a) 33±4, b) 32±2 | MRI | 6, 12 |
Data is presented as mean±SD or median with IQR.
a) Treatment arm; b) Control arm.
↵* Numbers in bold show follow-up duration used in this meta-analysis.
BMC, bone marrow cell; EF-RNV, ejection fraction-radionuclide ventriculography; HD, high dose; LAD, left anterior descending artery; LD, low dose; LVEF, left ventricular ejection fraction; LV, left ventricle; NS, non-selected; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; PET, positron emission tomography; S, selected; SPECT, single-photon emission; TTE, transthoracic echocardiogram.